Supplementary Figure 10 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer

<p>Supplementary Figure 10. (A) Progression-free and (B) overall survival among all patients with stage III NSCLC according to ATM mutation status. (C) Progression-free and (D) overall survival among patients with stage III NSCLC who received concurrent chemoradiotherapy followed by durvalumab...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteur: Biagio Ricciuti (14951247) (author)
Andere auteurs: Arielle Elkrief (15055750) (author), Joao Alessi (15561455) (author), Xinan Wang (15561458) (author), Yvonne Li (15561461) (author), Hersh Gupta (15561464) (author), Daniel M. Muldoon (15561467) (author), Arrien A. Bertram (14954848) (author), Federica Pecci (15561470) (author), Giuseppe Lamberti (15024714) (author), Alessandro Di Federico (15561473) (author), Adriana Barrichello (15561476) (author), Victor R. Vaz (15561479) (author), Malini Gandhi (15561482) (author), Elinton Lee (15561485) (author), Geoffrey I. Shapiro (14961801) (author), Hyesun Park (15561488) (author), Mizuki Nishino (15561491) (author), James Lindsay (15032271) (author), Kristen D. Felt (15561494) (author), Bijaya Sharma (15561497) (author), Andrew D. Cherniack (14959412) (author), Scott Rodig (15561500) (author), Daniel R. Gomez (15561503) (author), Narek Shaverdian (15561506) (author), Mehrdad Rakaee (15561509) (author), Chaitanya Bandlamudi (15047205) (author), Marc Ladanyi (15050661) (author), Pasi A. Janne (15561512) (author), Adam J. Schoenfeld (15022025) (author), Lynette M. Sholl (15032729) (author), Mark M. Awad (14961722) (author), Michael L. Cheng (15561515) (author)
Gepubliceerd in: 2025
Onderwerpen:
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
Omschrijving
Samenvatting:<p>Supplementary Figure 10. (A) Progression-free and (B) overall survival among all patients with stage III NSCLC according to ATM mutation status. (C) Progression-free and (D) overall survival among patients with stage III NSCLC who received concurrent chemoradiotherapy followed by durvalumab maintenance according to ATM mutation status.</p>